276 related articles for article (PubMed ID: 27834845)
21. The potential role of YAP in Axl-mediated resistance to EGFR tyrosine kinase inhibitors.
Saab S; Chang OS; Nagaoka K; Hung MC; Yamaguchi H
Am J Cancer Res; 2019; 9(12):2719-2729. PubMed ID: 31911857
[TBL] [Abstract][Full Text] [Related]
22. GBA inhibition suppresses ovarian cancer growth, survival and receptor tyrosine kinase AXL-mediated signaling pathways.
Wang G; Ouyang B; Jing F; Dai X
Korean J Physiol Pharmacol; 2023 Jan; 27(1):21-29. PubMed ID: 36575930
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the Role of AXL in Fusion-positive Pediatric Rhabdomyosarcoma Identifies the Small-molecule Inhibitor Bemcentinib (BGB324) as Potent Chemosensitizer.
Danielli SG; Wurth J; Morice S; Kisele S; Surdez D; Delattre O; Bode PK; Wachtel M; Schäfer BW
Mol Cancer Ther; 2024 Jun; 23(6):864-876. PubMed ID: 38471796
[TBL] [Abstract][Full Text] [Related]
24. Targeting AXL Using the AVB-500 Soluble Receptor and through Genetic Knockdown Inhibits Bile Duct Cancer Growth and Metastasis.
Kim J; Nam G; Shin YK; Vilaplana-Lopera N; Jeung HC; Moon EJ; Lee IJ
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980768
[TBL] [Abstract][Full Text] [Related]
25. Structure-based drug discovery of novel fused-pyrazolone carboxamide derivatives as potent and selective AXL inhibitors.
Fang F; Dai Y; Wang H; Ji Y; Liang X; Peng X; Li J; Zhao Y; Li C; Wang D; Li Y; Zhang D; Zhang D; Geng M; Liu H; Ai J; Zhou Y
Acta Pharm Sin B; 2023 Dec; 13(12):4918-4933. PubMed ID: 38045061
[TBL] [Abstract][Full Text] [Related]
26. Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors.
Mollard A; Warner SL; Call LT; Wade ML; Bearss JJ; Verma A; Sharma S; Vankayalapati H; Bearss DJ
ACS Med Chem Lett; 2011 Dec; 2(12):907-912. PubMed ID: 22247788
[TBL] [Abstract][Full Text] [Related]
27. Structure-based discovery of potent inhibitors of Axl: design, synthesis, and biological evaluation.
Wu S; Liao M; Li M; Sun M; Xi N; Zeng Y
RSC Med Chem; 2022 Oct; 13(10):1246-1264. PubMed ID: 36325401
[TBL] [Abstract][Full Text] [Related]
28. Predicting the Specificity- Determining Positions of Receptor Tyrosine Kinase Axl.
Karakulak T; Rifaioglu AS; Rodrigues JPGLM; Karaca E
Front Mol Biosci; 2021; 8():658906. PubMed ID: 34195226
[TBL] [Abstract][Full Text] [Related]
29. The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression.
Goyette MA; Duhamel S; Aubert L; Pelletier A; Savage P; Thibault MP; Johnson RM; Carmeliet P; Basik M; Gaboury L; Muller WJ; Park M; Roux PP; Gratton JP; Côté JF
Cell Rep; 2023 Dec; 42(12):113604. PubMed ID: 38100352
[No Abstract] [Full Text] [Related]
30. Author Correction: The effect of inhibition of receptor tyrosine kinase AXL on DNA damage response in ovarian cancer.
Yeo XH; Sundararajan V; Wu Z; Phua ZJC; Ho YY; Peh KLE; Chiu YC; Tan TZ; Kappei D; Ho YS; Tan DSP; Tam WL; Huang RY
Commun Biol; 2023 Jul; 6(1):759. PubMed ID: 37474650
[No Abstract] [Full Text] [Related]
31. Editorial: Development of small molecule inhibitors and antibodies targeting AXL for tumor therapy and infectious disease control.
Pyo KH; Rahman SMM; Boraschi D
Front Oncol; 2022; 12():1121120. PubMed ID: 36703780
[No Abstract] [Full Text] [Related]
32. Correction: Axl Kinase as a Key Target for Oncology: Focus on Small Molecule Inhibitors.
Mol Cancer Ther; 2015 Jun; 14(6):1518. PubMed ID: 25998950
[No Abstract] [Full Text] [Related]
33. Retraction. A promiscuous liaison between IL-15 receptor and Axl receptor tyrosine kinase in cell death control.
Budagian V; Bulanova E; Orinska Z; Thon L; Mamat U; Bellosta P; Basilico C; Adam D; Paus R; Bulfone-Paus S
EMBO J; 2011 Feb; 30(3):627. PubMed ID: 21285977
[No Abstract] [Full Text] [Related]
34. Retraction Notice to: A FBXO7/EYA2-SCF
Shen JZ; Qiu Z; Wu Q; Zhang G; Harris R; Sun D; Rantala J; Barshop WD; Zhao L; Lv D; Won KA; Wohlschlegel J; Sangfelt O; Laman H; Rich JN; Spruck C
Mol Cell; 2024 Jun; 84(12):2398. PubMed ID: 38823387
[No Abstract] [Full Text] [Related]
35. Correction to: A pathway map of AXL receptor-mediated signaling network.
Dagamajalu S; Rex DAB; Palollathil A; Shetty R; Bhat G; Cheung LWT; Prasad TSK
J Cell Commun Signal; 2021 Mar; 15(1):149. PubMed ID: 32990931
[No Abstract] [Full Text] [Related]
36. A pathway map of AXL receptor-mediated signaling network.
Dagamajalu S; Rex DAB; Palollathil A; Shetty R; Bhat G; Cheung LWT; Prasad TSK
J Cell Commun Signal; 2021 Mar; 15(1):143-148. PubMed ID: 32829427
[No Abstract] [Full Text] [Related]
37. Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies.
Kariolis MS; Miao YR; Diep A; Nash SE; Olcina MM; Jiang D; Jones DS; Kapur S; Mathews II; Koong AC; Rankin EB; Cochran JR; Giaccia AJ
J Clin Invest; 2017 Jan; 127(1):183-198. PubMed ID: 27893463
[TBL] [Abstract][Full Text] [Related]
38. Giving AXL the axe: targeting AXL in human malignancy.
Gay CM; Balaji K; Byers LA
Br J Cancer; 2017 Feb; 116(4):415-423. PubMed ID: 28072762
[TBL] [Abstract][Full Text] [Related]
39. Reprogramming the immunological microenvironment through radiation and targeting Axl.
Aguilera TA; Rafat M; Castellini L; Shehade H; Kariolis MS; Hui AB; Stehr H; von Eyben R; Jiang D; Ellies LG; Koong AC; Diehn M; Rankin EB; Graves EE; Giaccia AJ
Nat Commun; 2016 Dec; 7():13898. PubMed ID: 28008921
[TBL] [Abstract][Full Text] [Related]
40. Molecular Pathways: Oncologic Pathways and Their Role in T-cell Exclusion and Immune Evasion-A New Role for the AXL Receptor Tyrosine Kinase.
Aguilera TA; Giaccia AJ
Clin Cancer Res; 2017 Jun; 23(12):2928-2933. PubMed ID: 28289089
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
